» Articles » PMID: 6151206

Duration of Benzodiazepine Clinical Activity: Lack of Direct Relationship with Plasma Half-life. A Comparison of Single Vs Divided Dosage Schedules of Prazepam

Overview
Specialty Pharmacology
Date 1984 Jan 1
PMID 6151206
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The anxiolytic activity and tolerance of two dosage schedules of prazepam, a long plasma half-life benzodiazepine, were compared under double-blind conditions in two groups of 10 inpatients each who met Research Diagnostic Criteria for Generalized Anxiety Disorder and presented chronic and severe symptomatology. Patients received prazepam 40 mg per day on one of two dosage schedules: divided dosage (DD) - 10 mg in the morning and at noon and 20 mg in the evening; or single dosage (SD) - 40 mg in the evening. The 3 weeks of therapy were preceded and followed by 1 week of wash-out for baseline and follow-up assessments, which were performed weekly with the Hamilton Anxiety Scale, Clinical Global Impression, rating of morning drowsiness and evening worsening of symptoms, and patient self-rating of anxiety by means of a visual analogue scale performed both in the morning and in the afternoon. The results showed a clear superiority of the DD over the SD schedule: better anxiolytic efficacy on the Hamilton Anxiety Scale (P less than 0.0005) and on both morning and afternoon visual analogue scales (P less than 0.01 and P less than 0.0002); less morning drowsiness (P less than 0.0001); and steadier anxiolytic effect during the daytime, as globally rated by the investigator (P less than 0.0001) or measured by morning-afternoon differences on the visual analogue scale (P less than 0.005). These results suggest that plasma pharmacokinetics alone may not be sufficient to predict the duration of benzodiazepine anxiolytic activity.

Citing Articles

Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design.

Ansseau M, Doumont A, Thiry D, von Frenckell R, Collard J Psychopharmacology (Berl). 1985; 87(2):130-5.

PMID: 3931136 DOI: 10.1007/BF00431795.


Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography.

Shinotoh H, Iyo M, Yamada T, Inoue O, Suzuki K, Itoh T Psychopharmacology (Berl). 1989; 99(2):202-7.

PMID: 2552484 DOI: 10.1007/BF00442808.


Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Gupta S, ELLINWOOD E, Nikaido A, Heatherly D Pharm Res. 1990; 7(6):570-6.

PMID: 2367325 DOI: 10.1023/a:1015805908792.

References
1.
Breimer D, Jochemsen R, von Albert H . Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung. 1980; 30(5a):875-81. View

2.
Spitzer R, Endicott J, Robins E . Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry. 1978; 35(6):773-82. DOI: 10.1001/archpsyc.1978.01770300115013. View

3.
ANHALT H, Young R, Roginsky M . Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing. J Clin Psychiatry. 1980; 41(11):386-92. View

4.
Petursson H, Lader M . Withdrawal from long-term benzodiazepine treatment. Br Med J (Clin Res Ed). 1981; 283(6292):643-5. PMC: 1506756. DOI: 10.1136/bmj.283.6292.643. View

5.
Goldberg H, Finnerty R . A double-blind study of prazepam versus placebo in single daily doses in the treatment of anxiety. Compr Psychiatry. 1977; 18(2):147-55. DOI: 10.1016/0010-440x(77)90058-x. View